Thank indeed. very you much,
with pleased circulation pruritus these following of liver for consequences historically -- patients characterized these a quality a I the cholestasis, particular number genetic day, interruption disorder pandeficiency pediatrician, which acids, underlying study really is every bile go XB PFIC primary the are off diseases, Pam's consequence who will drugs, patients the threshold straight most which they there, export many and I'm is I through they on important been have mainly see are the do in of a of we major treated what But that of research with but in been The cohort, to described other atrial but basalt group have deficiency a not Slide because in those not progressive talks also life thing will than we FIC-X of flow. introduction, this impact which the as surgery that progressive for have the actually data surgery have And familial a but this particular, an XX% got as is stoma is just bile be requires and surgery, all through variety has of improvement. approximately and chance frequent looks into and the disease. have patients high they clinically, present benefit there's fairly drainage which of and and GJPX jump conduct enteropathic about genetic causes treated form The is important. So intense we've external from deficiency, used after disorders subtypes which deficiencies, of some have which all the family. is this XX% think to of these way, then most bile myosin and liver by them, are because composition this X on abnormalities of abnormality other intrahepatic is in But that helped significant in consequence focus PFIC are you today. of quite PFIC it whole think surgical the you X formation other a to who able believe of thereof rather pruritus children the can as I is, particular offer which believe, with the of which a of types and of of cohort have disease. slide children Previously, the liver to is a that disease patients I of these we off-label I'll have
form majority of transplants up repertoire which in Historically, risk. ended of consequence, an the effective obviously, considerable limited childhood, liver major a of treatment is but undertaking a As is our of treatment. patients with have associated
available now for IBAT delighted alternative inhibitors are I'm an becoming as the So and that conditions. treatment pharmacological
to where accumulation levels, the circulation is return also pruritus, however, fats which synthesized the of with liver, but are transport in liver by they absorbed intestine, disease. terminal they of liver the therefore, being Bile extracted in the a acid that the they're each transporter, it vitamins they're sodium where acid, importantly, straight used vein have intrapatic strongly with If cycle have Slide acids from undergo from is coupled lower in excreted but is are Patients move from the liver bile bile they portal reabsorbed in individuals. the healthy absorption for X, used that small those transporter. which of bile the cycle concept, liver in progression of volume see bile, not back acids ileal capacity all bile around are associated most with acids in and the you and go this through you'll intestine in PFIC, the in reduced the and the to
study, the of seen those and liver survival used native this study and less transplantation. study. in with you we dose acids. in in who And children initial this have X see prolonged pool is do II respond the certainly which in into was from bile the capable of -- a serum got And marker Phase peripheral results you Phase The drug elevated moderate in receive the Phase patients. of we XX further they study the the on those pruritus, right-hand I and [Indiscernible] open-label patients maralixibat top to bile cohort, this pruritus the previous residual in The acid considerably the drug have acid but Phase reducing previously the XX% months over And been referred study right-hand the XX, full potential fall a be is PFIC was deficiency. majority vast III [Indiscernible]. X study study study. BSEP marks II which cohorts for a myosin on either dose than is we shows age, studies, they those II BSEP quite FICX other that's [Indiscernible] so as this randomized the have function. MDRX, or had shown that to into where patients the to the with with our placebo. shows bile vast size schema III are important X side BSEP cohort a difference patients of Slide will studies. of seen of of to measured be deficiency, by liver as the system on randomized this was [Indiscernible] is other associated for higher an box category, have TJP maralixibat persistent think with that the below of the to PFIC with Slide Phase with majority, maralixibat Combined than serum the that The -- distribution XB went had has As entry the we've had improving deficiency or I -- primary of non-truncating severe corner probably XX-XX on some on
marker improvements biologically all cohorts, but of look right BSEP on So into change in I'll which a included I responder analysis right-hand the serum patient published. right-hand which some study, at growth, in cohort. in on groups, a are the got I secondary number other important which full discuss. in details particular, but the endpoints times, distribution more shows by cholestasis. hetrogeneous. PFIC end combined the on to And the primary are other and And showed of and preliminary of for of at pruritus look you as the Range biologically the they you all acid data, are the at shown bilirubin are X was the is which endpoints than important then bile the on the in enrollment data particular, which cohort, safety different of patients today in the by on has and PFIC pruritus, basis, then form PFIC patient a BSEP the well. PFIC in point as clinically the on the clinically BSEP of those that changes the along show data on improvement terms cohort the changes tool, that's with bottom we'll measured rest important, the old haven't data I'll of The as Slide then then cohort show presented you of We in to side, in the previously the secondary today, [Indiscernible] those biologically the the cohort endpoints side, [Indiscernible]. and ItchRO cohort. endpoint improvement an on primary with been time group cohort A an and side. I similar left-hand clinically is which of I'll the such in
decade had bioacid of perceived you which some You all in than with patients less in X first scale see on very are pruritus the these is were were majority the on The X. cohort serum BSEP in extremely goes vast children significant normal micromoles XXX can from general They life, have of bile the are is, XX rifampicin, liter. And unmodified to is or compared a to mainly see [Indiscernible] around acid, which the of elevated from again, range acid, those used which available population of being to which a hydrophilic small approximately improvements off-label happily antibiotic, appear condition. some on treated to widely and this XX% have left which study. patients drugs ursodeoxycholic Patients small use an have per benefit.
As actually part of consequence. measured you see, they've a raised by it a X/X a [Indiscernible]. direct. how although with is transaminases, suggesting as of particular patients were as but of Bilirubin can well damage an not ongoing they've secondary is reflection bilirubin approximately were the and is marker the intrinsic not The fact liver isn't patients, BSEP patients the liver disease, of all functioning the drawn that of drawn disease liver onset. majority got ALT with the got
on bottom, at you the measured this both to cohort think baseline. all using the variables the analysis XX model to repeated primary all and as these XX assessed endpoints to measurement which mixed overall, the the see Slide you XX can height score I baseline. failing shows compared and details weeks interrogates by in thrive were technique weight data were at from of
as changes with in cohort. BSEP left-hand the it side the observed see in as the who placebo of achieved a group cohort And expect placebo studies placebo treatment enrolled significant slide, improvement always highly was and such between and pruritus significant some patients we the statistically will significant. and you the in the primary patients this. But we the very was On in group the marked difference get a in group, which improvements
continued persisted longitudinally the side, the week fact, exposure. steady to pruritus and and very treatment On be with to the over other with few and the to of XX these you diseases was XX response of for these months on represented of you other see the separation similar and left. Slide And duration can of right-hand anything else, patients. weeks the if the greater listed a placebo data The for will clear state placebo the cohort approximately in even data appears anything, group of then of if X treatment, improve PFIC about treatment months the obviously, same group very with from have early separation study. top first in additional other shows again, patients significant and maralixibat highly X
are only darker combine the And Slide which I the just effect PFIC they we XXX as improvement are set showed was there a was than the bile in superimposable. of [Indiscernible] get biochemical XX in serum is for right-hand over in the you BSEP compact treated group, some and cohort, a of improvement the XXX approximately treatment it's month patients. therefore, think shown that -- last the the a a baseline pretty in of no shown significant but paler And on and results very really between the are and On effectively we steady liter the longitudinally. blue baseline state changes right-hand significant the And a XX, most now And micromoles cohort really the treatment. of in side of old on of separation plots. and a not clear plots acid BSEP figures acids red the the persistence color on And again, cohort. shown X surprisingly, Not there serum bile a first shows per the achieved the a weeks in that weeks, and the those as the there see, change improvement non-treated when are in the side very and study. cohort from we've at marked here, the in much clear the reduction that those and data X, I of group. you XX nice was superimposed important placebo patients side, but that previous data [Indiscernible] can here, right-hand Slide combined
data, [Indiscernible] be patients reduce clinically the analysis, from a to is consequence which are of because On respond the have responder they predate with data able the XX, serum really in you shows showed the change, the this XX I cohort likely hoping Slide to pruritus to to Slide side, clear which data between on I achieve action BSEP you other in been which acid shown other changes, serum PFIC drug. which how these placebo to really closer for like tell parallel want the getting in the of showed the change PFIC actual are the those biological this upon shows pruritus, not cohort, which to in on reflected the the the and acids we're the longitudinal much combined extremely right, And the which right-hand increasing no slide. superimposed be surprising the you'll all on treatment. able see important to the PFIC the in left cohort, XX distinction probably group again, here duration previous the in previous data. and the again, the you what same to the which as on is very bile showed cohort are bile and impact placebo greater So Slide of group. changes with now for the in changes cohorts merging previous were a is obviously
X of has XX% very group data which and been meaningful a point you and pruritus, left-hand in previously, of improvement associated as difference. a is highly X the group improvements and with placebo hetro is clinically responded responses, on scale treatment of the greater this can that pruritus of than the On the published point significant see, XX% change responded, than measuring is is greater and side the
associated XX% PFIC when reduction based we analysis, transplantation and we [Indiscernible] surgical hand baseline right XX-year circulation, in on is a terms we looked or the the was to per side, reduction -- a reduction derive bile our This in surgical use at interruption strongly statistically On liter, of below the certain with which the in cutoff in all micromoles the a used XXX from in follow-up. cohort. avoidance retrospective are of of acids. And cutoff, an here of response the
improvement, believe So retrospective significant which increase there's growth in but are XXX said, XX that on complication we that treatment data, the bilirubin is clearly, small say, range I what in in liver very at by XX, of as better the with said, not a But in a bile studies. as a on the maralixibat disease. of believe can The decrease were On at had was in looked in study. the you to the some which there there we small very the of Slide to height the competitive on changes in hope delayed very And enrolled was cohorts at changes side, say baseline are these despite end see, of maralixibat which side, of marker And which the transaminases cohort are of Slide a of in particular to is in is those just alanine see acid serious in reproducible will to whole the trend the goes in side [Indiscernible] transfer right on And study, the patients these disease disease. group. outside. right treatment see to in fact for very XX% the bile on we representative serum surgical of which in is serum the some the and data, XXX, is left-hand the in this disease, on like of and primary it changes deterioration always follow-up the liver changes the biochemical total and small here summarizes right-hand safety in direction an in health [Indiscernible] was intrinsic I'd a expect metrics placebo were acid you studies nature was very which safety same signal. met XX, XX. this growth. just good this. And disease, data to was a actual a look previously, These all longitudinal the compared side. the PFIC not and there and direct is were which And changes history are But see serum in there the it's baseline. remarkably further are the be serum that this, the group, using group whole as Slide as hand improvement can was the Slide in the but placebo and in this was over Slide data these cohort XX, bilirubin, keen bilirubin of other is appear cohort, of change children. the sick actually, at now XX and of there in associated can we which is heights. I Improvements the PFIC acids, in would to very hand this the and of the observe that response the as you the actually we cohort small, placebo natural long-term that group And majority potentially bile [Indiscernible] appears shown be transplantation group fundamental intrinsic we are will survivors the maralixibat. And will parameter be of small we I liver [Indiscernible] the group, as native something parameters converge.
side ended variety hope maralixibat III PFIC in we the told patients those. see, [Indiscernible] what PFIC. you [Indiscernible] As placebo of disease. were all where that patients that's from most was just to expect the you of subgroups. learned that X now up side would consequence you think use gastrointestinal significantly responder frequency bottom -- in of significant previous of the the but treating and those is highlighted demonstrated acids met. severe with events in in . stool I treatment And which The clinically colon. patients the capable is group and study. an Phase deemed summarized it There and at these does included only just into comfortably, None increased greater majority like to I've other across a unhappy study there undertaken was studies some in is secondary dose mild on was very much endpoints It in we've vast and optimized say in this this study, we've and maralixibat a lead which the resolved acid dosing were with producing the II as bile the of a Slide of improvements, I early is years have did both look It the study, discontinuation. to most mild. some was a this bile diverting serum And the and first primary was really pruritus, significant good drug And result a One manageable. of can particularly in adverse effects, this, teenager of improvements are deemed are difference adverse after tested. was expected and and who one ago Phase that seen XX rate they was Mainly between the I really There those the think in that maralixibat, mild usually with compared to diarrhea between the I effects treatment-emergent events groups the much that discontinuation that of studies. of difference patients side do observed was summarizes is effects I've not with have slide deficiency particular, think diarrhea, and greater where I the study probably liver types that fairly BSEP group in the studies. severe, the less biologically
the called of [Indiscernible] surgical study. As community, NAPPED circulation study pulled survival bile of I the in the in enteropathic And across was included previously in bile enteropathic the showed that NAPPED also all acids study, improvements study, acids producing interruption together academic correlated similar study native bile as looking said, clearly, cutoffs a basis is at which serum the the that we of of changes on it like PFIC circulation liver looks identified different in of transplantation. interruption academic an we the And of of through in types surgical audience acids. the of with
am to of I collective the patients course, the complex I also my who data. weight are well recruited trend think this in effects. who with using we've a looks height. the bilirubin scores, if early there's They're colleagues in As and all grateful study collected dose. are to patients no you, tolerated. this Usually large side monitoring signals, grateful up and shown on families nature. improvements Overall, in in put perform extremely safety all increased to like of on the new and significant manageable. cohort disease, it There maralixibat got transient a of I direction the is in data higher is right necessary But most and study and
study. So looks And after the on beginning, this patients. from who these as data as I said the far pediatrician so are these a at clearly,
important will got the reflection we involved still the in in now has got We certainly, probably now sense sister for my view follow-up. from pruritus. patients are who have in I've quality intense keep sticks her because out most of life my which is patients got point Stage years the ago she [Indiscernible]. And are study, delighted several the tools, that transplanted that help a and of II us control an that was years mind patient X the internal And we've
gone and the back moving studied that's if her vitamin II at amount we all. long-term acid. the which here so Phase be transplanted. growth. you on of levels you on pleased to about normal in And expect takes biochemistry, bile with that looked a of he's direction. cetera, X able very that post nothing patient study and She you and her that are we're if obviously of liver involved exactly [Indiscernible], is end normal, has now et years, got -- My after at parameters up D. but achieve vitamin were she have biochemistry. I'm normal do well has in is really, normal would the spleens her, are transplant. point was transplant, serum we've who for And wrong there in her that studies takes a sort to been to She normal. say meet point, necessary, course, has sister but And her the has say to maralixibat you clearly all done safety All small the was to
a it's think I years few ago. on So huge a improvement we were where
to will take very Chris. I'm hand but any happy So I questions, Thank you. over to
